Ningbo Menovo Pharmaceutical Co Ltd

Record trading volume for Ningbo Menovo Pharmaceutical (603538) after its JH389 probiotic capsule trial announcement, sparking a 7‑day‑6‑board streak and high liquidity.

Shanghai market trends: pharma and aerospace stocks rise—Ningbo Menovo, Shenjian, and Hengyuan lead gains as investors chase high‑growth China sectors.

Explore Ningbo Menovo Pharmaceutical’s market outlook, valuation, and its role in China’s booming innovation drug sector – key insights for investors.

Ningbo Menovo Pharmaceutical Co Ltd has seen a significant surge in investor confidence, with a 9.97% increase in its stock price and a net inflow of 44.79 million CNY, positioning the company for strong growth prospects.

Ningbo Menovo Pharmaceutical Co Ltd is experiencing significant market activity and growth prospects, driven by investor interest and the company’s strategic focus on the innovative drug sector.

Ningbo Menovo Pharmaceutical Co., Ltd. has shown a strong performance on the Shanghai Stock Exchange, with its stock price reaching a 52-week high and maintaining a significant market capitalization.